Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Sanofi and GlaxoSmithKline (GSK) have signed an agreement with the UK Government to supply up to 60 million doses of a potential Covid-19 vaccine.
The vaccine is based on Sanofi’s recombinant protein-based technology, used to produce an influenza vaccine, as well as GSK’s pandemic adjuvant technology.
Sanofi is responsible for the clinical development and registration of the vaccine. The company expects to begin a Phase I / II clinical trial in September, followed by a Phase III trial by the end of the year.